SHELBY BROOKS: Open Payments
NPI 1912561739 · TOPEKA, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,352 in 64 payments from 17 companies in 2025. Trend: 2023 $1,054 · 2024 $1,099 · 2025 $1,352
Food & beverage: $1,292Education: $60
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 15 | $353 |
| GlaxoSmithKline, LLC. | 12 | $260 |
| Amgen Inc. | 9 | $155 |
| Novartis Pharmaceuticals Corporation | 7 | $141 |
| SANOFI-AVENTIS U.S. LLC | 1 | $60 |
| GENZYME CORPORATION | 3 | $57 |
| ARS Pharmaceuticals Operations, Inc. | 3 | $54 |
| VERTEX PHARMACEUTICALS INCORPORATED | 2 | $43 |
| BioCryst US Sales Co., LLC | 2 | $38 |
| Integra LifeSciences Corporation | 2 | $35 |
Products named: NUCALA, FASENRA, TEZSPIRE, DUPIXENT, AIRSUPRA, Rhapsido, XOLAIR, TRELEGY ELLIPTA.
Industry payments across KS — which companies pay providers there.
